Amorphous Solid Dispersion Tablets Overcome Acalabrutinib pH Effect in Dogs

Amorphous Solid Dispersion Tablets Overcome Acalabrutinib pH Effect in Dogs

Calquence<sup>®</sup> (crystalline acalabrutinib), a commercially marketed tyrosine kinase inhibitor (TKI), exhibits significantly reduced oral exposure when taken with acid-reducing agents (ARAs) due to the low solubility of the weakly basic drug at elevated gastric pH. These drug–drug...

Full description

Bibliographic Details
Main Authors: Deanna M. Mudie, Aaron M. Stewart, Jesus A. Rosales, Nishant Biswas, Molly S. Adam, Adam Smith, Christopher D. Craig, Michael M. Morgen, David T. Vodak
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Pharmaceutics
Subjects:
acalabrutinib
amorphous solid dispersion
acid-reducing agent
bioavailability enhancement
kinase inhibitor
pH effect
Online Access:https://www.mdpi.com/1999-4923/13/4/557

Internet

https://www.mdpi.com/1999-4923/13/4/557

Similar Items